Cargando…

Case Report: Therapeutic Response to Chemo-Immunotherapy in an Advanced Large Cell Lung Carcinoma Patient With Low Values of Multiple Predictive Biomarkers

Immune checkpoint inhibitors have revolutionized the treatments of lung cancers, and multiple predictive biomarkers alone or in combination help clinicians with the appropriate therapeutic selections. Recently, chemo-immunotherapy has been recommended for treating advanced non-small cell lung cancer...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Guihua, Chai, Qin, Xiao, Yajie, Peng, Wenying, Teng, Miao, Wang, Jingyi, Lin, Hanqing, Su, Xiaofan, Wu, Lin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7876253/ https://www.ncbi.nlm.nih.gov/pubmed/33584678 http://dx.doi.org/10.3389/fimmu.2020.607416

Ejemplares similares

Enhanced Therapeutic Efficacy of Combining Losartan and Chemo-Immunotherapy for Triple Negative Breast Cancer
por: Zhao, Qing, et al.
Publicado: (2022)

Reprogramming of Tumor-Associated Macrophages with Anticancer Therapies: Radiotherapy versus Chemo- and Immunotherapies
por: Genard, Géraldine, et al.
Publicado: (2017)

Editorial: Combining chemo/radio therapy and immunotherapy for cancers—perfect mix of old and new
por: Slaney, Clare Y., et al.
Publicado: (2023)

Soluble PD-1: Predictive, Prognostic, and Therapeutic Value for Cancer Immunotherapy
por: Khan, Muhammad, et al.
Publicado: (2020)

Biomarkers for immunotherapy in esophageal cancer
por: Wang, Xuelian, et al.
Publicado: (2023)

Computational Recognition of a Regulatory T-cell-specific Signature With Potential Implications in Prognosis, Immunotherapy, and Therapeutic Resistance of Prostate Cancer
por: Ju, Mingyi, et al.
Publicado: (2022)

Two types of biomarker-dependent chemo-immunotherapy for pancreatic cancer?
por: Melief, Cornelis J.M.
Publicado: (2022)

GNPNAT1 is a potential biomarker correlated with immune infiltration and immunotherapy outcome in breast cancer
por: Yuan, Renjie, et al.
Publicado: (2023)

LncRNA Expression Profiles in Systemic Lupus Erythematosus and Rheumatoid Arthritis: Emerging Biomarkers and Therapeutic Targets
por: Wu, Han, et al.
Publicado: (2021)

DNA Damage Repair Status Predicts Opposite Clinical Prognosis Immunotherapy and Non-Immunotherapy in Hepatocellular Carcinoma
por: Chen, Yunfei, et al.
Publicado: (2021)

Recurrence- and Malignant Progression-Associated Biomarkers in Low-Grade Gliomas and Their Roles in Immunotherapy
por: Teng, Chubei, et al.
Publicado: (2022)

The components of tumor microenvironment as biomarker for immunotherapy in metastatic renal cell carcinoma
por: Su, Jiaming, et al.
Publicado: (2023)

CTNNB1 Alternation Is a Potential Biomarker for Immunotherapy Prognosis in Patients With Hepatocellular Carcinoma
por: Chen, Lin, et al.
Publicado: (2021)

Tertiary lymphoid structures predict the prognosis and immunotherapy response of cholangiocarcinoma
por: Shang, Taiyu, et al.
Publicado: (2023)

Potential Value of miR-221/222 as Diagnostic, Prognostic, and Therapeutic Biomarkers for Diseases
por: Song, Jialin, et al.
Publicado: (2017)

NOTCH4 mutation as predictive biomarker for immunotherapy benefits in NRAS wildtype melanoma
por: Li, Hongxia, et al.
Publicado: (2022)

IGFBP2 from a novel copper metabolism-associated biomarker promoted glioma progression and response to immunotherapy
por: Luo, Qisheng, et al.
Publicado: (2023)

Cold Tumors: A Therapeutic Challenge for Immunotherapy
por: Bonaventura, Paola, et al.
Publicado: (2019)

PD-L1: Biological mechanism, function, and immunotherapy in gastric cancer
por: Zhang, Yingzi, et al.
Publicado: (2022)

Comprehensive comparative analysis of prognostic value of serum systemic inflammation biomarkers for colorectal cancer: Results from a large multicenter collaboration
por: Xie, Hailun, et al.
Publicado: (2023)

Exploration of Novel Immunological Terms in Lung Cancer With Large Populations: Implications for Immunotherapy
por: Yao, Yuanshan, et al.
Publicado: (2022)

Predictive biomarkers of colon cancer immunotherapy: Present and future
por: Hou, Wanting, et al.
Publicado: (2022)

Editorial: Novel biomarkers for predicting response to cancer immunotherapy
por: Huangfu, Shuchen, et al.
Publicado: (2023)

Granzyme B in circulating CD8+ T cells as a biomarker of immunotherapy effectiveness and disability in neuromyelitis optica spectrum disorders
por: Shi, Ziyan, et al.
Publicado: (2022)

Prospects and feasibility of synergistic therapy with radiotherapy, immunotherapy, and DNA methyltransferase inhibitors in non-small cell lung cancer
por: Jie, Chen, et al.
Publicado: (2023)

The circadian rhythm key gene ARNTL2: a novel prognostic biomarker for immunosuppressive tumor microenvironment identification and immunotherapy outcome prediction in human cancers
por: Wu, Gujie, et al.
Publicado: (2023)

Research progress of extracellular vesicles as biomarkers in immunotherapy for non-small cell lung cancer
por: Ge, Yang, et al.
Publicado: (2023)

EGFR Mutation and 11q13 Amplification Are Potential Predictive Biomarkers for Immunotherapy in Head and Neck Squamous Cell Carcinoma
por: Dou, Shengjin, et al.
Publicado: (2022)

Noncoding RNAs as an emerging resistance mechanism to immunotherapies in cancer: basic evidence and therapeutic implications
por: Wang, Man, et al.
Publicado: (2023)

Putting Proteomics Into Immunotherapy for Glioblastoma
por: Chen, Liangyu, et al.
Publicado: (2021)

Durable Response to Immunotherapy With Antiangiogenic Drug in Large-Cell Lung Carcinoma With Multiple Fulminant Postoperative Metastases: A Case Report
por: Luo, Zhilin, et al.
Publicado: (2021)

Immunotherapy in cervical cancer: From the view of scientometric analysis and clinical trials
por: Xing, Yang, et al.
Publicado: (2023)

Leukotriene A(4) Hydrolase Is a Candidate Predictive Biomarker for Successful Allergen Immunotherapy
por: Ma, Ting-Ting, et al.
Publicado: (2020)

Tumor Burden and Immunotherapy: Impact on Immune Infiltration and Therapeutic Outcomes
por: Kim, Samuel I., et al.
Publicado: (2021)

N(6)-Methyladenosine in Cancer Immunotherapy: An Undervalued Therapeutic Target
por: Quan, Chao, et al.
Publicado: (2021)

Editorial: Immunotherapy and small molecule inhibitors as combinational cancer therapeutics
por: Khan, Mohd Wajid Ali, et al.
Publicado: (2023)

The need to optimize chemotherapy regimens for chemo-immunotherapy
por: Inamura, Kentaro, et al.
Publicado: (2022)

CD8(+) T cell/cancer-associated fibroblast ratio stratifies prognostic and predictive responses to immunotherapy across multiple cancer types
por: Zheng, Xinlong, et al.
Publicado: (2022)

The expression pattern of Immune checkpoints after chemo/radiotherapy in the tumor microenvironment
por: Hassanian, Hamidreza, et al.
Publicado: (2022)

Chemo-immunoablation of solid tumors: A new concept in tumor ablation
por: Meng, Liangliang, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_0c9oh6s9vvjrdjtgifsjuvr55c